

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 28128

**Title:** Infliximab does not increase colonic cancer risk associated to murine chronic colitis

**Reviewer's code:** 00071220

**Reviewer's country:** Japan

**Science editor:** Yuan Qi

**Date sent for review:** 2016-06-27 15:04

**Date reviewed:** 2016-06-27 15:10

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

I had the opportunity to review a paper "Infliximab does not increase colonic cancer risk associated to murine chronic colitis", and I found very interesting. There is no problem to publish the manuscript.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 28128

**Title:** Infliximab does not increase colonic cancer risk associated to murine chronic colitis

**Reviewer's code:** 03254039

**Reviewer's country:** Japan

**Science editor:** Yuan Qi

**Date sent for review:** 2016-06-27 15:04

**Date reviewed:** 2016-07-13 11:23

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input checked="" type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

The authors examine the influence of Infliximab (IFX) on the development of chronic colitis-associated cancer in mice. They show that IFX does not affect the development of murine colitis-associated cancer and proliferation of intestinal epithelial cells. Based on these results, the authors conclude that IFX does not increase colonic cancer risk in colitis-associated cancer. This study suggests an important message that anti-TNF- $\alpha$  therapy may not affect the increase cancer risk in IBD patients. Minor comment In Figure 1A, any symbol should be inserted if there are statistical significant differences. Furthermore, inclusion of an x-axis line on the graphs (Figure 1A and 1B) is more standard.